MDACC Study No:2012-0626 ( NCT No: NCT01644253)
Title:A Phase 1b, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab or in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia
Principal Investigator:William G. Wierda
Treatment Agent:Rituximab; TRU-016
Study Status:Open
Study Description:The goal of this clinical research study is to learn more about how safe the
drug TRU-016 is to give in combination with rituximab or obinutuzumab to
patients with CLL. The potential effects of this drug will also be studied.

TRU-016 is a protein made to act like an antibody that is designed to find and
destroy certain cells. TRU-016 works against a certain kind of white blood
cell (a “B cell”). This means that it may decrease the number of B cells in
your blood. Decreasing the number of these B cells may slow the growth of CLL.

Rituximab and obinutuzumab are also antibodies that are designed to work
against B cells and decrease the number of B cells in your blood, which may
slow the growth of CLL.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Rituximab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Emergent Product Development Seattle, LLC
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults